# Oral Ipamorelin: What the Research Notes (Ipamorelin)

> Oral ipamorelin: plain ipamorelin is not orally bioavailable. Only engineered analogs reached ~10% oral absorption in dogs. What the research actually shows.

The honest answer to a heavily marketed format: plain ipamorelin doesn't survive the gut. Here's what the studies actually used.

## The short version

Searches for ipamorelin oral keep climbing as capsules and troches hit the market, so here's the plain-English reality up front: standard ipamorelin is **not** orally bioavailable. As a peptide, it gets broken down in the gut before it can act, and every piece of human and rodent data that matters used injection — intravenous or subcutaneous — not a pill [2]. The studies that achieved meaningful oral absorption did it with *engineered ipamorelin-derived analogs*, not ipamorelin itself, and even then only reached roughly 10% in dogs.

So if a product promises the benefits of injected ipamorelin in a swallowed form, the burden of proof is on it, and the published record doesn't back it. This page lays out what the research actually notes about route and absorption — the same honest treatment the rest of this zine gives the regulatory record.

## Why peptides struggle by mouth

Ipamorelin is a pentapeptide — a five-amino-acid chain [1]. The gut is built to dismantle exactly that kind of molecule: digestive enzymes and stomach acid treat a swallowed peptide like food, breaking it into fragments before much of anything reaches the bloodstream intact. Ipamorelin's design includes features — a non-natural amino acid (Aib) and two D-form residues — that resist enzymatic breakdown and extend its life in the body [1]. But "more stable than a naive peptide" is not the same as "survives the digestive tract," and the pharmacology bears that out: the characterized routes are injectable [2].

## What the routes data actually shows

The published routes for ipamorelin are intravenous, subcutaneous, intranasal, and intraperitoneal — all of which bypass first-pass digestion [2][5]. The human PK/PD work was IV [2]. Rodent bone and body-composition studies were subcutaneous [4]. Intranasal delivery reached about 20% bioavailability in rodents — better than oral, still a parenteral mucosal route, not a pill. The 2024 ferret study used intraperitoneal injection [5]. Oral bioavailability, where it appears at all, is reported only for **ipamorelin-derived analogs** specifically engineered for gut survival — around 10% in dogs — not for ipamorelin as sold [2]. The takeaway for the oral format is blunt: the molecule people are actually buying was studied as an injectable.

## What this means for oral products

No controlled human study has shown that swallowed ipamorelin produces the GH pulse the injectable does, and the pharmacology argues against it [2]. Combine that with the broader regulatory picture — never FDA-approved, dropped from the 503A compounding list in 2024 [13], one failed human trial [3] — and an "oral ipamorelin" product is stacking two unproven claims at once: that this specific compound works as marketed, and that it works in a form the data doesn't support. This site sells nothing and recommends nothing; it just notes that the format with the most marketing has the least research behind it. For the routes that *were* studied and at what doses, see the [Ipamorelin research](/research) and dosage pages.

---

It says shop; it sells nothing — just a zine pinning ipamorelin's never-approved, pulled-from-the-503A-list, banned-in-sport record next to what the studies actually measured.